An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations by Makowski, M.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/171249
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Proteomics 2016, 16, 417–426 417DOI 10.1002/pmic.201500327
RESEARCH ARTICLE
An interaction proteomics survey of transcription factor
binding at recurrent TERT promoter mutations
Matthew M. Makowski1∗, Esther Willems1∗, Jun Fang3∗∗, Jiyeon Choi3, Tongwu Zhang3,
Pascal W. T. C. Jansen1, Kevin M. Brown3∗∗ and Michiel Vermeulen1,2
1 Radboud Institute of Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands
2 Cancer GenomiCs Netherlands, Utrecht, The Netherlands
3 Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute,
National Institutes of Health, Bethesda, MD, USA
Received: August 11, 2015
Revised: October 21, 2015
Accepted: November 5, 2015
Aberrant telomerase reactivation in differentiated cells represents a major event in oncogenic
transformation. Recurrent somatic mutations in the human telomerase reverse transcriptase
(TERT) promoter region, predominantly localized to two nucleotide positions, are highly preva-
lent in many cancer types. Both mutations create novel consensus E26 transformation-specific
(ETS) motifs and are associated with increased TERT expression. Here, we perform an un-
biased proteome-wide survey of transcription factor binding at TERT promoter mutations in
melanoma. We observe ELF1 binding at both mutations in vitro and we show that increased
recruitment of GABP is enabled by the spatial architecture of native and novel ETSmotifs in the
TERT promoter region. We characterize the dynamics of competitive binding between ELF1
and GABP and provide evidence for ELF1 exclusion by transcriptionally active GABP. This
study thus provides an important description of proteome-wide, mutation-specific binding at
the recurrent, oncogenic TERT promoter mutations.
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1 Introduction
Telomerase reactivation, associated with senescence bypass
and essentially unlimited proliferative capacity, is a classic
hallmark of cancer [1,2]. However, because telomerase is typ-
ically silenced in differentiated cells, telomerase reactivation
is thought to proceed through transcriptional mechanisms
[3]. A number of factors have previously been implicated in
TERT reactivation via various transcriptional pathways [4–6].
Importantly, two landmark studies identified two recurrent
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somatic mutations (C228T and C250T) in the TERT pro-
moter region in melanoma and other cancers [7, 8]. Subse-
quent work confirmed TERT promoter mutations occur with
high frequency in many cancer subtypes, in some cases ap-
proaching or exceeding the penetrance of canonical driver
coding mutations [9, 10]. Genome-wide analysis further con-
firmed TERT promoter mutations as the most consistently
significantmutational hotspot across various cancer subtypes
[11, 12]. Intriguingly, the two TERT promoter mutations ap-
pear to be mutually exclusive, indicating potential functional
redundancy [7, 8].
More recent work has begun to unravel the func-
tional mechanisms by which TERT promoter mutations
exert their oncogenic effect. For example, TERT pro-
moter mutations were recently implicated in overcoming
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Significance of the study
Somatic mutations in the TERT promoter associated with
TERT reactivation during oncogenesis are common and
highly frequent in many different cancer subtypes. Under-
standing the mechanisms by which TERT promoter mu-
tations exert their transcriptional effect is crucial towards
clarifying their role in oncogenesis. Therefore, uncover-
ing the ensemble of transcription factors that bind specif-
ically to recurrent TERT promoter mutations directly im-
plicates potential upstream effectors in TERT reactivation.
Furthermore, transcription factors that bind specifically at
similar motifs can actively compete for binding at the same
site in vivo. Therefore, characterizing the biochemical prop-
erties of competitive transcription factor binding at TERT
promoter mutations reveals a complex and dynamic pattern
of regulation at these sites. Ultimately, this study furthers
our understanding of specific transcription factor binding at
TERT promotermutations and contributes to our knowledge
of transcriptional regulation in oncogenic TERT reactivation.
differentiation-associated transcriptional silencing of TERT
expression, effectively extending telomere length and
potentially contributing to tumorigenic immortalization
[13, 14]. Additionally, both mutations create novel E26
transformation-specific (ETS) transcription factor motifs
within the TERT promoter region [7, 8]. However, the ex-
act factor or factors influencing TERT expression specifically
via promoter mutation sites remained elusive until a recent
study demonstrated that GABP, an ETS-family transcription
factor, was a major functional interactor [15]. The identifi-
cation of GABP as a mutation-specific interactor is partic-
ularly interesting, as multiple transcriptionally active bind-
ing modes for GABP have been previously been reported,
including a heterodimer (GABPA/B) and a heterotetramer
(GABPA2/B2) [16–20]. The heterotetrameric binding mode
of GABP was associated with TERT promoter mutation spe-
cific interactions. In particular, a precise spatial architecture
between native ETS motifs and novel, mutation-specific ETS
motifs was indicated as crucial for tetrameric GABP binding
[15]. Very recently, another report indicated that mutation
specific GABP binding is concurrent with a switch to active
chromatin marks [21].
Despite progress in elucidating the molecular function
of TERT promoter mutations, most of the studies thus far
have targeted ETS-family factors. Complementary to targeted
molecular studies, our group and others have previously es-
tablished workflows for AP-MS/MS based identification of
sequence specific protein-DNA binding on a proteome-wide
scale [22, 23]. Here, we perform an unbiased, proteome-wide
survey of TERT promoter mutation specific transcription fac-
tor binding. We identify specific binding of multiple fac-
tors, including ELF1/2 and ETV6, and we confirm GABP
as a direct, specific interactor in melanoma. We provide fur-
ther characterization of the spatial architecture that promotes
GABP binding at native and novel ETS motifs in the TERT
promoter. Additionally, we analyze competitive binding dy-
namics between ELF1 and GABP and propose a model in
which multimeric GABP binding to a native and novel ETS
motif excludes ELF1 and activates TERT expression. In sum,
this study provides an important molecular characterization
of proteome-wide transcription factor binding events that are
specific for recurrent, somatic mutations in the TERT pro-
moter, further extending our knowledge of the oncogenic
properties of this locus.
2 Materials and methods
2.1 Cell culture and nuclear lysate extraction
Melanoma cell lines were grown in adherent culture in RPMI
1640 (Gibco) supplemented with 10% FBS, 200 mM HEPES
(pH 7.9), 100 U/mL penicilin and 100 g/mL streptomycin
(Gibco).
Nuclear lysates were collected essentially as described pre-
viously [23]. Briefly, cells were incubated in hypotonic Buffer
A (10 mMHEPES (pH 7.9), 1.5 mMMgCl2, 10 mM KCl and
0.15% NP40). Cells were then lysed by dounce homogenizer.
Crude nuclei were collected by centrifugation and lysed in
Buffer C (420 mMNaCl2, 20 mMHEPES (pH 7.9), 20% (v/v)
glycerol, 2 mM MgCl2, 0.2 mM EDTA, 0.1% NP40, EDTA-
free complete protease inhibitors (Roche), and 0.5 mM DTT)
by rotation for 1 h at 4C. Nuclear lysates were collected as the
soluble fraction, snap frozen in liquid nitrogen, and stored at
–80C.
2.2 DNA pulldown and on-bead sample preparation
Oligo baits were ordered via custom synthesis from Biomers
with 5’-biotinylation of the forward strand (Supporting In-
formation Table 1). Oligos were combined with 1.5X mo-
lar excess of the reverse strand in 2X annealing buffer
(20 mM TRIS, pH 8.0, 100 mM NaCl and 2 mM EDTA)
and denatured at 98C for 10 min. Oligos were allowed to
anneal by cooling to room temperature overnight and subse-
quently stored at –20C. For each pulldown reaction, 20 L
bead slurry (10 L beads) of Streptavidin-Sepharose beads
(GEHealthcare)were used. According to experimental design
(Fig. 1A), each pulldown was performed in duplicate for out-
lier calling. Label swappingwas performedbetween replicates
to eliminate labeling bias. All pulldowns from each labeling
C© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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Figure 1. AP-MS/MS identifies TERTpromotermutation specific interactors. (A) Aworkflow forMS-based identification of sequence-specific
DNA interacting proteins. (B) Custom oligos were 5’ biotinylated and designed to cover both the C228T and C250T mutation sites. Oligos
are referred to by mutation as shown in the diagram. (C) AP-MS/MS analysis of the C228T TERT promoter mutation interactors. Interactors
with a ratio of at least 3 IQR (inter-quartile range) in both experiments are colored in red. Ratios are shown after log2 transformation. Labels
were swapped between replicates to avoid labeling bias, hence specific interactors showing a high ratio in one experiment, and a low ratio
in the other. Outlier proteins not observed consistently across experiments are noted at the bottom of the chart. (D) Band-shift experiments
with the C228T TERT promoter mutation oligo. Recombinant human protein was incubated with annealed oligo and resolved on a TBE
polyacrylamide gel. Band-shift experiments for each protein-oligo combination were resolved on the same gel at the same exposure. (E)
JASPAR motif prediction agrees with mutation specific ELF1 and GABPA binding at C228T [29, 30]. The underlying wild-type sequence
surrounding the C228T mutation is shown beneath the JASPAR motifs, and the mutation is indicated by arrow. (F) AP-MS/MS analysis of
C250T TERT promoter mutation interactors. (G) Band-shift experiments with the C250T TERT promoter mutation oligo and recombinant
human protein. (H) JASPAR motif prediction agrees with mutation specific ELF1 and GABPA binding at C250T. The underlying wild-type
sequence surrounding the C250T mutation is indicated below the JASPAR motifs as in (E).
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reaction (forward and reverse) were performed simultane-
ously. Beads were washed once with 0.1% NP40 in 1X PBS
and once with DNA binding buffer (DBB: 1 M NaCl, 0.05%
NP40, 10mMTRIS, pH8.0 and 1mMETDA). Annealed oligo
(500 pmol) was diluted in 600 L DBB final volume and ro-
tated for 30 min at 4C. Subsequent steps were all carried
out at 4C. Beads with immobilized oligonucleotides were
washed once with DBB and twice with protein binding buffer
(PBB: 150 mM NaCl, 0.25% NP40, 50 mM TRIS, pH 8.0,
EDTA-free complete protease inhibitors, and 1 mM DTT).
Nuclear extracts (500 g) and 10 g of competitor DNA
(5 g poly-dIdC, 5 g poly-dAdT) were added to beads in
a 600 L final volume. For all AP-MS/MS analyses, nuclear
extract fromUACC903 cells (C228T-positive) was used. Beads
were incubated for 90 min on a rotation wheel at 4C. The
beads were then washed three times with PBB and two times
with 1X PBS. All supernatant was carefully removed with a
syringe. The proteins were reduced in elution buffer (2 M
urea, 10 mM DTT, and 100 mM ammonium bicarbonate)
for 20 min with shaking at room temperature. Samples were
alkylated by addition of 50 mM iodoacetamide (IAA) in the
dark with shaking at room temperature for 10 min. Proteins
were then subjected to on-bead trypsin digestion (0.25 g)
for 2 h at room temperature plus shaking. The supernatant
was transferred to a new tube and digested with an additional
0.1 g trypsin overnight.
2.3 On-stagetip dimethyl labeling
Tryptic peptideswere purified onC18 stage-tips (without acid-
ification) as described previously [24]. Buffer A was 0.1%
formic acid and Buffer B was 80% acetonitrile and 0.1%
formic acid. On-StageTip dimethyl labeling was performed as
described previously [25]. Briefly, 300 L of labeling reagent
(16.2 L 37% CH2O (light) or 30.0 L 20% CD2O (medium)
plus 6 mg sodium cyanoborohydride in 3 mL of labeling
buffer [10 mM NaH2PO4, 35 mM Na2HPO4]) was applied
to the StageTip and spun through at 2200 × g for 10 min.
StageTips were then washed once with 100 L of Buffer A
and stored at 4C for MS analysis.
2.4 Mass spectrometry analysis
Labeled samples were eluted from the StageTips with 30 L
of Buffer B while combining the respective light andmedium
labeled pairs into the same tube. Acetonitrile was evapo-
rated by SpeedVac centrifuge at room temperature. After
resuspension with 7 L of Buffer A, 5 L of sample was
loaded onto a 30 cm column (heated at 40C) packed in-house
with 1.8 mReprosil-Pur C18-AQ (Dr Maisch). The peptides
were eluted from the column using a gradient from 7 to 32%
Buffer B in Buffer A over 120 min at flow rate 250 nL/min
using an Easy-nLC 1000 (Thermo Fisher Scientific).
C228T, C250T, and 2MT samples were eluted and sprayed
directly into a Thermo Fisher QExactive mass spectrome-
ter. The mass spectrometer was operated in top ten data-
dependent acquisition mode. Target values for full MS were
set to 3e6AGC target and amaximum injection time of 20ms.
Full MS were recorded at a resolution of 70 000 over a scan
range of 300–1650 m/z. Target values for MS/MS were set at
1e5 AGC target with a maximum injection time of 120 ms.
The MS/MS spectra were recorded at a resolution of 17 500.
The isolation width was set to 3.0m/z, the collision energy to
NCE = 25, and the intensity threshold to 8.3e2. Dynamic ex-
clusionwas enabled for 20 s. Peptideswith single or unknown
charge state were excluded for MS/MS analysis.
C228T+ETS samples were eluted and sprayed directly into
a Thermo Fisher Orbitrap Fusion Tribridmass spectrometer.
Target values for full MS were set to 4e5 AGC target and a
maximum injection time of 50 ms. Full MS were recorded
at a resolution of 120 000 at a scan range of 400–1500 m/z.
Most intense precursors with a charge state between 2 and 7
were selected forMS/MS analysis, with an intensity threshold
of 5000 and dynamic exclusion for 60 s. Target values for
MS/MSwere set at 1e4AGC target with amaximum injection
time of 35 ms. Ion trap scan rate was set to ‘rapid’, with an
isolation width of 1.6 m/z and collision energy of 35%.
2.5 Data analysis
Raw MS spectra were analyzed using MaxQuant software
(version 1.5.1.0) with standard settings [26, 27]. For dimethyl
labelled samples, the respective built in N-terminal and ly-
sine modification for dimethyl labeling was specified under
“labels”. Carbamidomethylation was specified as a fixedmod-
ification on cysteines. N-terminal acetylation and methion-
ine oxidation were allowed as variable modifications. Trypsin
was selected as specific enzyme, and two missed cleavages
were allowed. Data was searched against the human UniProt
database (fasta file downloaded 2014.09.03) using the inte-
grated search engine. The search was performed with a mass
tolerance of 4.5 ppm mass accuracy for the precursor ion
and 20 ppm for fragment ions. Peptides and proteins were
both accepted at an FDR of 0.01. For quantification, at least
two ratio counts were required. Protein identifications and
calculated ratios are included as the proteinGroups output
file from MaxQuant analysis (Supporting Information Table
2). Plots were generated with Python essentially as described
previously [28]. Briefly, protein identifications were filtered
for contaminants and reverse hits. Proteins groups were re-
quired to have two identified peptides, of which at least one
was unique, to be considered as identified. The required out-
lier significance was 3.0 IQRs (inter-quartile range) for both
forward and reverse experiments.
2.6 Band-shift experiments
Band-shift experiments were performed by incubating
20 fmol of biotin labeled double stranded oligos with re-
combinant human ELF1 protein (Origene, TP760629) or
C© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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recombinant GABPA/B (Abnova, GABPA: H00002551-P01,
GABPB: H00002553-P01) in a total volume of 20 L of pro-
tein binding buffer (PBB: 150 mM NaCl, 0.25% NP40, 50
mM TRIS, pH 8.0, and 1 mM DTT) for 30 min. For GABP
experiments, GABPA and GABPB were mixed at equimo-
lar concentrations for 20 min at room temperature prior to
addition of the oligo, in GABP experiments, the molecular
weights listed in the figures refers to the total molecular
weight of protein used (GABPA/B combined). The resulting
protein complexes were resolved on 4–20% TBE gels (Bio-
rad) in a Mini-PROTEAN tetra cell (Biorad) at 100 V for ap-
proximately 3 h in 1X TBE. Samples were transferred onto
a nylon membrane (Biodyne) in a Trans-Blot Turbo Trans-
fer semi-dry transfer system (Biorad) at 400 mA for 10 min.
Membranes were UV cross-linked and oligos were detected
using streptavidin-HRP conjugate and a chemiluminescent
substrate (Chemiluminescent Nucleic Acid Detection Mod-
ule, Pierce). Rawdata fromall bandshift experiments reported
in this study is presented in Supporting Information Fig. 1.
2.7 Western blotting
DNA pulldowns were performed as described above. After
the final PBS wash, samples were resuspended in MilliQ wa-
ter plus 1X sample buffer and boiled at 95C for 10 min.
Samples were then resolved on a poly-acrylamide gel, trans-
ferred to a nitrocellulose membrane, blocked with 5% milk,
and incubated with primary antibody at 4C overnight (ELF1:
Santa Cruz, sc-631; GABPA: Santa Cruz, sc-22810). Samples
were then incubated with HRP-conjugated secondary anti-
body (Dako) for 1 h at room temperature, and imaged using
an ECL Western Blotting Substrate (Pierce).
2.8 RNA and genomic DNA extraction
RNA was extracted using an RNeasy Plus Mini Kit (Qiagen).
Genomic DNA was isolated using the ZR genomic DNATM
kit (D3050, ZYMOResearch) and assessed by Nanodrop 8000
(Thermo Scientific).
2.9 Long PCR and sequencing of TA clones
PCR was carried out using genomic DNAs from 7 UACC
melanoma cell lines as indicated in Fig. 4A. The PCR primers
used were: GGGCCGCAGCTGCTCCTTGTCG and CAGGC-
CGGGCTCCCAGTGG.PCR conditionswere 98C for 10min
to initially denature, followed by 38 cycles of: 98C for 30 s,
60C for 30 s, and 72C for 90 s, with a 7-min final extension
at the end. The PCR products were cloned into TA vector (Life
Technologies). Single colonies of bacteria were selected and
PCR sequenced in 96-well plate format. The PCR reactionwas
performed in the same manner as above. Sanger sequencing
was used to determine the sequences of the PCR product.
2.10 Real-time quantitative PCR and allelic specific
TERT expression
Gene expression levels were quantified by quantitative real-
time PCR using TaqMan assays for TERT (Hs00972656_m1),
ELF1 (Hs01111177_m1), ELF2 (Hs00959420_g1), GABPA
(Hs01022016_m1), and GAPDH (cat#4333764) from Life
Technologies. siRNA knockdown experiments were per-
formed using siRNAs purchased from Dharmacon target-
ing GABPA (D-001810-01-05), ELF1 (L-012669-00-0005), and
ELF2 (L-012754-00-0005). A non-targeting scrambled siRNA
was used as the control (D-001810-01-05). Gene expression
levels of TERT, ELF1 and ELF2 were normalized to GAPDH.
Allele specific TERT expression was determined using an
allelic discrimination TaqMan assay for rs2736098 (assay
C_26414916_20, Life Technologies), and the gene expression
of each allele of TERTwas also normalized to the gene expres-
sion of GAPDH. Each experiment was performed in triplicate
and repeated three times.
3 Results and discussion
3.1 ELF1 binds specifically to both TERT promoter
mutations
We used an AP-MS/MS based workflow to identify the
proteome-wide interactomes of both TERT promoter mu-
tations (Fig. 1A). Oligo baits were designed to encompass
bothmutation sites concurrently, with onemutation per oligo
(Supporting Information Table 1, Fig. 1B). For AP-MS/MS
analysis, we used UACC903 metastatic melanoma derived
cell lines, characterized asC228T-positive (unpublished data).
We identified ELF1 and ELF2 as specific interactors at both
the C228T and C250T mutation sites and ETV6 as a spe-
cific interactor at the C250T mutation site (Fig. 1C and F).
We confirmed the specificity and robustness of the ELF1 in-
teraction via bandshift with recombinant protein (Fig. 1D
and G). JASPAR in silico motif prediction agrees with mu-
tation specific binding for ELF1 and GABPA (Fig. 1E and
H) [29, 30]. However, we did not observe a specific GABP
interaction with either TERT promoter mutation by MS anal-
ysis. Intriguingly, band-shift experiments using pure, recom-
binant GABP revealed a subtle preference for the C228T and
C250Tmutations over thewild-type sequence (Fig. 1D andG).
This potentially indicates that the stabilizing effect of a sin-
gle mutation (and thus a single canonical motif) is sufficient
to relatively increase recombinant GABP binding in vitro.
Indeed, comparison between previous GABP electrophore-
sis analysis and TERT promoter bandshift experiments sug-
gests that the low-mobility complex we observed is indeed
the GABPA/B heterotetramer [31]. However, GABP concen-
trations in nuclear lysates are likely far lower than those used
in bandshift experiments, which explains why GABP was
not identified by AP-MS/MS; our data thus suggests that
ELF1 is a significant, specific interactor of single ETS motifs
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Figure 2. Analysis of protein
binding patterns at the TERT
promoter double mutation. (A)
Oligos were designed as be-
fore, but encompassing both
common TERT promoter muta-
tions. (B) AP-MS/MS analysis of
the doublemutation (2MT) oligo
containing both TERT promoter
mutations. (C) Band-shift exper-
iments with the 2MT TERT pro-
moter oligo and recombinant
human protein. (D) Competitive
binding experiments between
ELF1 andGABP at the 2MT TERT
promotermutation oligo. Molar-
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unit.
created by recurrent mutations in the TERT promoter. How-
ever, TERT promoter mutation-specific GABP binding at sin-
gle novel ETS motifs, while present, appears to be of lower
affinity.
3.2 Analysis of transcription factor binding at the
TERT promoter double mutation
We were interested in the observed mutual exclusivity of the
TERTpromoter C228T andC250Tmutations; are theymerely
functionally redundant, or are there combinatorial binding
modes generated by the second ETS motif that preclude
its appearance in vivo? To address this, we applied our MS
workflow to the TERT promoter double mutation sequence
(Fig. 2A). We observed the same set of ETS-family transcrip-
tion factors as significant interactors: ELF1, ELF2, and ETV6
(Fig. 2B).Wewere again able to confirmspecificELF1binding
by band-shift assay (Fig. 2C). Moreover, with the double mu-
tation sequence, we observed GABPA as a mutation-specific
interactor by MS analysis and by band-shift assay (Fig. 2B
and C). Importantly, this agrees with a model where hetero-
tetrameric binding at two precisely spaced ETS motifs stabi-
lizes GABP binding relative to the wild-type sequence. Fur-
thermore, our data suggests that the two novel ETSmotifs on
the 2MT oligo may facilitate a greater degree of GABP stabi-
lization or occupancy compared with either C228T or C250T
independently.
We conducted competitive binding assays by band-shift
and observed substantially greater ELF1 binding compared
with GABP in equimolar conditions (assuming tetrameric
binding) (Fig. 2D). Of note, we observed doublet bands for
ELF1 corresponding to monomeric binding or simultaneous
binding by two ELF1 molecules, but this doublet pattern was
not seen for GABP. Our data therefore supports the robust
monomeric binding of ELF1 and stable but lower affinity het-
erotetrameric binding of GABP to the 2MT oligo. We did not
observe any other differential binding events at the double
mutation, indicating that both mutations are likely function-
ally redundant. Therefore, the double mutation is likely not
strongly selected for during cancer progression compared
with either mutation independently.
3.3 GABP binding at novel and native ETS motifs
excludes ELF1 and activates TERT expression
To resolve the discrepancy between ELF1 binding at TERT
promoter mutations in vitro and its lack of transcriptional
effect in vivo, we again performed AP-MS/MS analysis of
TERT promoter mutations, utilizing the C228T mutation
with two upstream native ETS motifs as a representative case
(Fig. 3A)[15]. This oligo design facilitated study of combinato-
rial binding with novel and native ETS motifs. Indeed, recent
work indicates that in the case of 250T, GABP still binds
using ETS-195 and ETS-200 instead of upstream ETS mo-
tifs [15]. These native motifs (ETS-195, ETS-200) represent
a different spatial architecture with either C228T or C250T
compared to C228T and C250T with each other (in the case
of the 2MT oligo), which likely has implications for the mu-
tual exclusivity of C228T and C250T mutations in vivo. For
C228T+ETS, we observed robust and specific binding of
GABP by MS analysis, and we could confirm the relative
specificity of this binding by band-shift assay (Fig. 3B and C).
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promoter mutation binding.
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We observed increased GABP binding concurrent with a
reduction in specific ELF1 and ELF2 binding; indeed, neither
reached significance at thresholds chosen in our previous
analysis. By competition band-shift assay, we were able to
directly compare ELF1 and GABP binding using both the
C228T and the C228T+ETS oligos. With the C228T oligo,
we observed relatively higher ELF1 binding compared with
GABP in equimolar conditions (Fig. 3D). However, with the
C228T+ETS oligo, we observed increased binding for GABP
in equimolar conditions (Fig. 3E). This supports our MS
analysis indicating that heterotetrameric GABP binding ex-
cludes ELF1 by occupying both the native and the novel ETS
motifs present in this sequence. This further indicates that
the stabilizing effect of a single TERT promoter mutation,
in conjunction with binding at native ETS motifs present
in C228T+ETS recruits GABP binding more robustly than
does 2MT, C228T or C250T. Furthermore, by western blot
we were able to support our MS and band-shift data, showing
increased ELF1 binding over wild-type at the C228T, C250T,
2MT, and to a lesser extent the C228T+ETS sequences, and
increased GABP binding over wild-type at the C250T, 2MT,
and C228T+ETS sequences but not the C228T sequence
(Fig. 3F). This strongly indicates that the GABP binding ob-
served at C228T+ETS critically depends on the native ETS
motif, as no specific binding is seen at C228T. Also, preferen-
tial binding at C250T but not C228T, suggests GABP binding
at 228T versus C250T might operate under different kinetics
[15, 32].
To study the relationship between GABP, ELF1, and ELF2
binding and TERT expression in vivo, we used a PCR-based
Sanger sequencing approach to identify seven melanoma
cell lines with both a heterozygous germline SNP variant
(rs2736098) and a haplotype-phased heterozygous TERT pro-
moter mutation. In these cell lines, we observed mono-allelic
TERT expression in which the expressed SNP allele always
correlated with a phased TERT promoter mutation (Fig. 4A).
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+-C10.0<754CCAU
+-C10.0<205CCAU
-+T001>2951CCAU
-+T001>0491CCAU
+-C10.0<1332CCAU
Figure 4. GABP activates mono-allelic TERT expression via promoter mutations. (A) TERT expression is mono-allelic and correlates with
promoter mutation status. Mono-allelic TERT expression was assayed at rs2736098. Expression of only one allele was observed. The
expressed allele correlated with a phased TERT promoter mutation as observed by PCR-based Sanger sequencing. (B) In the UACC903
melanoma cell line, GABPA knockdown substantially reduces TERT expression, while combined ELF1/2 knockdown minimally reduces
TERT expression. Experiments were performed in triplicate and repeated three times. Error bars represent standard error of the mean.
(C) In the UACC1113 melanoma cell line, GABPA knockdown substantially reduces TERT expression, while combined ELF1/2 knockdown
minimally reduces TERT expression.
Then, we used siRNA-mediated knockdown to discern the
direct transcriptional effects of ELF1/2 and GABPA on TERT
expression. In two separate cell lines, we observed a substan-
tial reduction in TERT expression upon GABPA knockdown
but onlyminimally reducedTERT expressionupon combined
ELF1/2 knockdown (Fig. 4B and C). Thus, this data strongly
indicates that TERT reactivation proceeds via mono-allelic
TERT expression exclusive to the promoter mutation phased
chromosome. Upon displacement of minimally activating
ELF1 or ELF2, GABP binding induces a robust transcrip-
tional response driving TERT expression. This study suggests
a model where binding of heterotetrameric, transcription-
ally active GABP at novel and native ETS motifs effectively
precludes ELF1 occupancy at the TERT promoter mutations
(Fig. 5).
4 Concluding remarks
Understanding dynamic, specific interactions between tran-
scription factors and the cognate DNA motifs they bind is
crucial towards elucidating their mechanisms of transcrip-
tional regulation. ForTERTpromotermutations, understand-
ing these dynamic binding specificities is of particular im-
portance as transcriptional activation is directly correlated
with oncogenic outcomes. This study utilizes an unbiased
proteome-wide approach to identify dynamic interplay be-
tween GABP and ELF1 via their specific interactions with
the TERT promoter mutations. This study also highlights the
importance of considering both native motifs and the spatial
architecture of DNAbaits when performingDNA-protein AP-
MS/MS experiments. The combinatorial nature of transcrip-
tion factor binding is often difficult to predict, and this study
offers a cautionary note that oligo baits of different lengths
or different sequence/motif compositionsmight produce dis-
crepant results even for the same locus. Indeed, as this study
indicates, when using oligos designed to minimally cover a
SNP or a cancermutation, biologically important interactions
may be overlooked.
Although most ETS-transcription factors are reported to
bindmonomerically, cooperative, antagonistic, and combina-
torial effects are common [33]. For example, Bell et al. use an
elegant bioinformatics analysis to indicate that strongGABPA
binding sites from ENCODE ChIP-seq tracks correlates with
multiple motifs spaced in a manner suggesting dimeriza-
tion [15, 34]. This periodic feature is unique to GABPA and
was not seen in ELF1 ChIP-seq tracks, suggesting that ELF1
in contrast binds monomerically. Indeed, GABP is known
to be the only obligate multimer among ETS-family tran-
scription factors [17,19,20]. Intriguingly, competitive binding
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Figure 5. A model for ELF1 exclusion by heterotetrameric GABP
at TERT promoter mutations. (A) ELF1 binds in vitro at novel
ETSmotifs created by TERT promotermutations. However, GABP
binds with high affinity at novel and native ETS motifs and ex-
cludes ELF1 from binding.
between GABP and another ETS factor, PU.1, has been seen
at the CD18 promoter, yet this competition cooperatively
drives CD18 expression [31]. Recent reports have indicated
that diverse combinatorial effects are crucial in the activat-
ing function of the TERT promoter mutations, specifically
in cooperation with native ETS-motif binding factors [15,32].
Although our data indicates that ELF1 knockdown has only
a mild effect on downstream TERT expression (which seems
to be driven predominantly by GABP), we cannot exclude the
possibility of combinatorial effectswith ELF1 or other natively
binding factors in the TERT core promoter.
This study highlights the dynamic nature of transcription
factor binding at the recurrent TERT promoter mutations
and points towards a complex picture of oncogenic transcrip-
tional regulation at this locus. We present a model where
stable, heterotetrameric, transcriptionally active GABP ex-
cludes monomeric ELF1 (Fig. 5). In doing so, we confirm
the identification of GABP as a mutation-specific interactor
in melanoma and contribute to our knowledge of regulatory
mechanisms at this important locus.
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